Now, research has found that higher levels of light pollution are associated with a greater prevalence of Alzheimer’s disease, the most common cause of dementia.

The FDA has approved the sBLA for once every 4 weeks lecanemab-irmb (Leqembi®) intravenous maintenance dosing.

MALVERN, Pa. - Annovis Bio Inc. (NYSE: ANVS), a clinical-stage drug platform company trading near its 52-week low of $2.99, has announced the initiation of a Phase 3 trial for its Alzheimer's disease ...